Other substances

Entecavir

A guanine analogue inhibitor of the hepatitis B virus.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Entecavir is a synthetic 2-deoxyguanosine analogue which is metabolized in vivo into a 5-triphosphate metabolite, which competes with dGTP during hepatitis B virus RNA reverse transcription. This leads into inhibition of the viral replication (NCIt).

Entecavir on DrugBank
Entecavir on PubChem
Entecavir on Wikipedia

Synonyms

Entecavir triphosphate

Marketed as

BARACLUDE; ENTECAVIR

C=C1[C@H](C[C@@H]([C@H]1CO)O)N2C=NC3=C2N=C(NC3=O)N

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model Preprint In silico	in silico			Feb/02/2020
A Library of Nucleotide Analogues Terminate RNA Synthesis Catalyzed by Polymerases of Coronaviruses Causing SARS and COVID-19 Preprint	in vitro		immediate termination of the polymerase reaction	Apr/25/2020
Morphological Cell Profiling of SARS-CoV-2 Infection Identifies Drug Repurposing Candidates for COVID-19 Preprint	Huh7 cells			May/27/2020
Drug repurposing of anti-infective clinical drugs: Discovery of two potential anti-cytokine storm agents Small molecule Animal model	Male C57BL/6 J mice; murine peritoneal macrophages; human peripheral blood mononuclear cells	4.55	Alleviate acute lung injury in mice. Inhibit LPS-stimulated TNF-α and IL-10 in models based on murine peritoneal macrophages or human peipheral blood mononuclear cells.	Aug/23/2020

AI-suggested references

Link	Publication date
Low risk of hepatitis b reactivation in patients with severe COVID-19 who receive immunosuppressive therapy	Aug/18/2021
Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Tocilizumab-Containing Treatment	Mar/09/2021
A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19	Jun/18/2020
SARS-CoV-2 RdRp Inhibitors Selected from a Cell-Based SARS-CoV-2 RdRp Activity Assay System.	Aug/11/2021

Export (.csv)